209 related articles for article (PubMed ID: 30036229)
1. Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery.
Castro BGR; Dos Reis R; Cintra GF; Sousa MMA; Vieira MA; Andrade CEMDC
Int J Gynecol Cancer; 2018 Oct; 28(8):1520-1528. PubMed ID: 30036229
[TBL] [Abstract][Full Text] [Related]
2. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
3. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
5. Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
Baldewpersad Tewarie NMS; van Driel WJ; van Ham M; Wouters MW; Kruitwagen R;
Gynecol Oncol; 2021 Aug; 162(2):331-338. PubMed ID: 34147284
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
7. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
Timmermans M; van der Aa MA; Lalisang RI; Witteveen PO; Van de Vijver KK; Kruitwagen RF; Sonke GS
Gynecol Oncol; 2018 Sep; 150(3):446-450. PubMed ID: 30001834
[TBL] [Abstract][Full Text] [Related]
8. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
9. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
10. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
[TBL] [Abstract][Full Text] [Related]
11. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E
Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
[TBL] [Abstract][Full Text] [Related]
14. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
Drews F; Bertelli G; Lutchman-Singh K
Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
[TBL] [Abstract][Full Text] [Related]
15. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
16. Primary and Interval Debulking Surgery Provide Similar Survival and Platinum Sensitivity Outcomes in Advanced Ovarian Cancer: A Retrospective Study.
Glover O; Asher V; Bali A; Abdul S; Collins A; Phillips A
Anticancer Res; 2020 Jul; 40(7):3925-3929. PubMed ID: 32620633
[TBL] [Abstract][Full Text] [Related]
17. Radical Surgical Procedures in Advanced Ovarian Cancer and Differences Between Primary and Interval Debulking Surgery.
Mitsopoulos V; Innamaa A; Lippiatt J; Plevris N; Biliatis I
Anticancer Res; 2020 Oct; 40(10):5869-5875. PubMed ID: 32988917
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
[TBL] [Abstract][Full Text] [Related]
19. Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis.
Sehouli J; Savvatis K; Braicu EI; Schmidt SC; Lichtenegger W; Fotopoulou C
Int J Gynecol Cancer; 2010 Nov; 20(8):1331-40. PubMed ID: 21051973
[TBL] [Abstract][Full Text] [Related]
20. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
Pepin K; Bregar A; Davis M; Melamed A; Hinchcliff E; Gockley A; Horowitz N; Del Carmen MG
Gynecol Oncol; 2017 Dec; 147(3):612-616. PubMed ID: 28988028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
